News for Metropolis Healthcare Limited (METROPOLIS.NS)

The acquisition, routed through its wholly owned subsidiary Metropolis Histoxpert Digital Services Private Limited, aligns with the company’s ongoing ‘String of Pearls’ strategy.

Metropolis Healthcare acquires DAPIC in INR ₹35.01 crore deal, expanding presence in North India's diagnostic market.

NSE announced the exclusion of five stocks: Apollo Tyres, Deepak Nitrite, Escorts Kubota, MRF, and Ramco Cements from the F&O segment starting June. This follows earlier removals, with 16 more stocks exiting by February 2025. Markets rebounded on Friday after an initial dip.

Ameera Shah, Managing Director of Metropolis Healthcare, speaks about the company’s growth plans, the competitive landscape, pricing strategies, and the role of technology in diagnostics.

Acquisition aligns with the company’s strategy of integrating regional diagnostic chains into its network.

Metropolis Healthcare acquires Agra-based Scientific Pathology, expanding presence in Uttar Pradesh's diagnostic market.

Starting February 28, 2025, 16 stocks including United Breweries and PVR Inox will exit the derivatives segment, trading only in the cash market. February 27 is the last day to trade their F&O contracts. The exclusion follows the December 20 announcement by NSE.

This announcement comes after a previous decision to add six companies to the F&O segment, namely Castrol India, Gland Pharma, NBCC, Phoenix Mills, Solar Industries, and Torrent Power.

BNP Paribas favours sectors with strong growth prospects like private sector banks, IT

The NSE of India will include six new stocks in the Futures and Options segment from January 31, 2025. The stocks are Castrol India, Gland Pharma, NBCC, Phoenix, Solar Industries India, and Torrent Power. Details about market lot and scheme of strikes will be announced on January 30, 2025.

Zerodha - India's biggest stock broker offering the lowest, cheapest brokerage rates for futures and options, commodity trading, equity and mutual funds

NSE has announced the exclusion of 16 securities, including Abbott India, PVR Inox, and Gujarat Gas, from the F&O market starting Feb. 28, 2025, as part of new SEBI guidelines aimed at improving liquidity and preventing manipulation.

The Rs 246.8 crore deal includes 55% financing in cash and 45% through an equity swap.

Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare, discussed the growth potential of the Indian oncology market, and the need for advanced cancer testing.

Indian benchmark equity indices, the Sensex and Nifty, experienced their fifth consecutive decline on Friday, recording their worst weekly performance in over two years. Escalating tensions in the Middle East and rising foreign outflows contributed to investor unease. The Nifty 50 index fell 0.93% to 25,014, while the S&P BSE Sensex decreased by 0.98% to 81,688.

Indian indices fell sharply on Thursday, dragged by Middle East tensions. Nifty closed at 25,250, down 2.12%. Analyst Rupak De sees a bearish trend reversal, with support at 25,070. Tejas Shah sees potential for a minor pullback rally, with support at 25,200-25,050 and resistance at 25,475-25,700.

Indian indices ended flat amid profit booking in energy stocks. Analysts anticipate volatility as geopolitical tensions rise and support levels for Nifty are observed around 25,650-700.

The Nifty index ended flat after a strong initial hour of trading, facing resistance around 23,400. Despite this, the short-term trend remains positive as the index stayed above 23,300. In the near term, the index is likely to continue consolidating within the 23,300-23,500 range. A decisive breakout above 23,500 could potentially trigger a rally towards 23,800.

Based on the OI percentage, a total of 44 stocks were on the short-covering list which included Exide Industries, Coromandel International, Mahanagar Gas, Birlasoft, and Dr Lal PathLabs.